Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma

The efficacy of sequential everolimus, an orally administered inhibitor of mammalian target of rapamycin (mTOR), was proven in a placebo-controlled phase III study, where median progression-free survival was 4.9 vs 1.9 months for placebo (hazard ratio: 0.33, P < 0.001). Placebo crossovers (80%) c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sun, Maxine, Abdollah, Firas, Schmitges, Jan, Jeldres, Claudio, Shariat, Shahrokh F, Perrotte, Paul, Karakiewicz, Pierre I
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2011
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3818936/
https://ncbi.nlm.nih.gov/pubmed/24198635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OAJU.S13283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados